Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Global Bronchiectasis Market - Industry Trends and Forecast to 2028

Published by Data Bridge Market Research Private Limited Product code 991794
Published Content info 570 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Bronchiectasis Market - Industry Trends and Forecast to 2028
Published: January 1, 2021 Content info: 570 Pages
Description

Global bronchiectasis market is projected to register a CAGR of 6.0% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.

Market Segmentation:

Global Bronchiectasis Market, By Disease Type (CF Bronchiectasis and Non-CF Bronchiectasis), Severity (Mild to Moderate and Moderate-to-Severe), Type (Diagnosis and Treatment), Drugs Type (Branded and Generics), Route of Administration (Oral, Parenteral and Inhalation), End User (Hospitals, Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and Rest of Middle East and Africa) Industry Trends and Forecast to 2028.

Some of the major factors contributing to the growth of global bronchiectasis market are:

  • Rising patient population suffering from bronchiectasis
  • Growing diagnostic rate

Market Players:

The key market players for global bronchiectasis market are listed below:

  • Abbott
  • HERSILL
  • Home Oxygen Company
  • Inogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Medline Industries, Inc
  • Ache Laboratories Farmaceuticos S.A.
  • Horizon Therapeutics plc
  • Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.)
  • Trudell Medical International
  • GlaxoSmithKline plc.
  • AstraZeneca
  • Pfizer Inc.
  • Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
  • Novartis AG
  • Teva Pharmaceutical USA Inc.(A Subsidiary of Teva Pharmaceutical Industries Ltd.)
  • Sun Pharmaceutical Industries Ltd.
  • Bayer AG
  • Dr. Reddy's Laboratories Ltd.
  • Sunovion Pharmaceuticals Inc. (a subsidiary of Sumitomo Dainippon Pharma Co., Ltd.)
  • Viatris Inc.
  • Covis Pharma
  • Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila)
  • Cipla Inc.
  • Electromed, Inc.
Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF GLOBAL BRONCHIECTASIS MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 DISEASE TYPE LIFELINE CURVE
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.9 DBMR MARKET POSITION GRID
  • 2.10 VENDOR SHARE ANALYSIS
  • 2.11 MARKET DRUGS TYPE COVERAGE GRID
  • 2.12 SECONDARY SOURCES
  • 2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PIPELINE ANALYSIS

5 GLOBAL BRONCHIECTASIS MARKET: LAWS AND REGULATIONS

6 EPIDEMIOLOGY

7 MARKET OVERVIEW

  • 7.1 DRIVERS
    • 7.1.1 RISING PATIENT POPULATION SUFFERING FROM BRONCHIECTASIS
    • 7.1.2 GROWING GERIATRIC POPULATION
    • 7.1.3 RISING NUMBER OF SMOKERS AND CONSUMPTION OF ALCOHOL
    • 7.1.4 TECHNOLOGICAL ADVANCEMENT FOR DISEASE TESTING
    • 7.1.5 GROWING DIAGNOSTIC RATE
  • 7.2 RESTRAINTS
    • 7.2.1 HIGH COST OF DIAGNOSTIC TOOLS
    • 7.2.2 PRODUCT RECALLS
    • 7.2.3 INAPPROPRIATE REIMBURSEMENT POLICIES
  • 7.3 OPPORTUNITIES
    • 7.3.1 RISING AWARENESS FOR PREVENTION OF BRONCHIECTASIS IN PRIMARY AND SECONDARY CARE
    • 7.3.2 INCREASING HEALTHCARE EXPENDITURE
    • 7.3.3 INCREASE IN RESEARCH REGARDING THE BRONCHIECTASIS DISEASE
    • 7.3.4 AVAILABILITY OF GENERIC DRUGS IN UNDERDEVELOPED AND DEVELOPING COUNTRIES
  • 7.4 CHALLENGES
    • 7.4.1 COMPLICATIONS IN THE TREATMENT OF BRONCHIECTASIS
    • 7.4.2 LACK OF SKILLED PROFESSIONALS
    • 7.4.3 DIAGNOSITIC CHALLENGES

8 IMPACT OF COVID-19

  • 8.1 PRICE IMPACT
  • 8.2 IMPACT ON DEMAND
  • 8.3 IMPACT ON SUPPLY CHAIN
  • 8.4 STRATEGIC DECISIONS FOR MANUFACTURERS
  • 8.5 CONCLUSION

9 GLOBAL BRONCHIECTASIS MARKET, BY DISEASE TYPE

  • 9.1 OVERVIEW
  • 9.2 NON-CF BRONCHIECTASIS
  • 9.3 CF BRONCHIECTASIS

10 GLOBAL BRONCHIECTASIS MARKET, BY SEVERITY

  • 10.1 OVERVIEW
  • 10.2 MILD TO MODERATE
  • 10.3 MODERATE TO SEVERE

11 GLOBAL BRONCHIECTASIS MARKET, BY TYPE

  • 11.1 OVERVIEW
  • 11.2 TREATMENT
    • 11.2.1 ANTIBIOTICS
      • 11.2.1.1 MACROLIDE
        • 11.2.1.1.1 AZITHROMYCIN
        • 11.2.1.1.2 CLARITHROMYCIN
        • 11.2.1.1.3 OTHERS
      • 11.2.1.2 AMOXICILLIN
      • 11.2.1.3 CEPHALOSPORIN
        • 11.2.1.3.1 SECOND-GENERATION CEPHALOSPORIN
        • 11.2.1.3.2 THIRD-GENERATION CEPHALOSPORIN
      • 11.2.1.4 AMINOGLYCOSIDE
        • 11.2.1.4.1 GENTAMICIN
        • 11.2.1.4.2 TOBRAMYCIN
      • 11.2.1.5 FLUOROQUINOLONE
      • 11.2.1.6 TETRACYCLINS
      • 11.2.1.7 TRIMETHOPRIM-SULFAMETHOXAZOLE
      • 11.2.1.8 COMBINATION THERAPY
    • 11.2.2 CORTICOSTEROIDS
      • 11.2.2.1 BUDESONIDE
      • 11.2.2.2 FLUTICASONE
      • 11.2.2.3 MOMETASONE
      • 11.2.2.4 FLUNISOLIDE
      • 11.2.2.5 OTHERS
    • 11.2.3 BRONCHODILATORS
      • 11.2.3.1 LONG-ACTING BRONCHODILATORS
        • 11.2.3.1.1 FORMOTEROL
        • 11.2.3.1.2 TIOTROPIUM
        • 11.2.3.1.3 SALMETEROL
        • 11.2.3.1.4 OTHERS
      • 11.2.3.2 SHORT-ACTING BRONCHODILATORS
        • 11.2.3.2.1 ALBUTEROL
        • 11.2.3.2.2 LEVALBUTEROL
        • 11.2.3.2.3 OTHERS
    • 11.2.4 MUCUS THINNING MEDICINE
      • 11.2.4.1 CARBOCISTEINE
      • 11.2.4.2 BROMHEXINE
      • 11.2.4.3 OTHERS
    • 11.2.5 AIRWAY CLEARANCE DEVICES
      • 11.2.5.1 OSCILLATING POSITIVE EXPIRATORY PRESSURE (PEP)
      • 11.2.5.2 INTRAPULMONARY PERCUSSIVE VENTILATION (IPV)
      • 11.2.5.3 POSTURAL DRAINAGE
      • 11.2.5.4 OTHERS
    • 11.2.6 OXYGEN THERAPY
      • 11.2.6.1 OXYGEN CONCENTRATORS
      • 11.2.6.2 COMPRESSED GAS OXYGEN
      • 11.2.6.3 LIQUID OXYGEN
    • 11.2.7 SURGERY
      • 11.2.7.1 BRONCHOSCOPY
      • 11.2.7.2 LUNG TRANSPLANT
    • 11.2.8 OTHERS
  • 11.3 DIAGNOSIS
    • 11.3.1 CHEST CT SCAN
    • 11.3.2 SPUTUM TEST
    • 11.3.3 PULMONARY FUNCTION TEST
    • 11.3.4 X-RAY
    • 11.3.5 OTHERS

12 GLOBAL BRONCHIECTASIS MARKET, BY DRUGS TYPE

  • 12.1 OVERVIEW
  • 12.2 BRANDED
  • 12.3 GENERICS

13 GLOBAL BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION

  • 13.1 OVERVIEW
  • 13.2 INHALATION
  • 13.3 ORAL
    • 13.3.1 TABLETS
    • 13.3.2 CAPSULES
    • 13.3.3 OTHERS
  • 13.4 PARENTERAL
    • 13.4.1 INTRAVENOUS
    • 13.4.2 SUBCUTANEOUS
    • 13.4.3 OTHERS

14 GLOBAL BRONCHIECTASIS MARKET, BY END USER

  • 14.1 OVERVIEW
  • 14.2 HOSPITALS
  • 14.3 CLINICS
  • 14.4 HOME HEALTHCARE
  • 14.5 OTHERS

15 GLOBAL BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL

  • 15.1 OVERVIEW
  • 15.2 HOSPITAL PHARMACY
  • 15.3 RETAIL PHARMACY
  • 15.4 ONLINE PHARMACY
  • 15.5 OTHERS

16 GLOBAL BRONCHIECTASIS MARKET BY GEOGRAPHY

  • 16.1 OVERVIEW
  • 16.2 NORTH AMERICA
    • 16.2.1 U.S.
    • 16.2.2 CANADA
    • 16.2.3 MEXICO
  • 16.3 EUROPE
    • 16.3.1 GERMANY
    • 16.3.2 FRANCE
    • 16.3.3 U.K.
    • 16.3.4 ITALY
    • 16.3.5 SPAIN
    • 16.3.6 NETHERLANDS
    • 16.3.7 RUSSIA
    • 16.3.8 SWITZERLAND
    • 16.3.9 BELGIUM
    • 16.3.10 TURKEY
    • 16.3.11 AUSTRIA
    • 16.3.12 NORWAY
    • 16.3.13 HUNGARY
    • 16.3.14 LITHUANIA
    • 16.3.15 IRELAND
    • 16.3.16 POLAND
    • 16.3.17 REST OF EUROPE
  • 16.4 ASIA-PACIFIC
    • 16.4.1 JAPAN
    • 16.4.2 CHINA
    • 16.4.3 INDIA
    • 16.4.4 AUSTRALIA
    • 16.4.5 SOUTH KOREA
    • 16.4.6 SINGAPORE
    • 16.4.7 MALAYSIA
    • 16.4.8 THAILAND
    • 16.4.9 INDONESIA
    • 16.4.10 PHILIPPINES
    • 16.4.11 VIETNAM
    • 16.4.12 REST OF ASIA-PACIFIC
  • 16.5 SOUTH AMERICA
    • 16.5.1 BRAZIL
    • 16.5.2 ARGENTINA
    • 16.5.3 PERU
    • 16.5.4 REST OF SOUTH AMERICA
  • 16.6 MIDDLE EAST AND AFRICA
    • 16.6.1 SAUDI ARABIA
    • 16.6.2 SOUTH AFRICA
    • 16.6.3 UAE
    • 16.6.4 ISRAEL
    • 16.6.5 KUWAIT
    • 16.6.6 EGYPT
    • 16.6.7 REST OF MIDDLE EAST AND AFRICA

17 GLOBAL BRONCHIECTASIS MARKET: COMPANY LANDSCAPE

  • 17.1 COMPANY SHARE ANALYSIS: GLOBAL
  • 17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
  • 17.3 COMPANY SHARE ANALYSIS: EUROPE
  • 17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

18 SWOT

19 COMPANY PROFILES

  • 19.1 ASTRAZENECA
    • 19.1.1 COMPANY SNAPSHOT
    • 19.1.2 REVENUE ANALYSIS
    • 19.1.3 COMPANY SHARE ANALYSIS
    • 19.1.4 PRODUCT PORTFOLIO
    • 19.1.5 RECENT DEVELOPMENTS
  • 19.2 GLAXOSMITHKLINE PLC.
    • 19.2.1 COMPANY SNAPSHOT
    • 19.2.2 REVENUE ANALYSIS
    • 19.2.3 COMPANY SHARE ANALYSIS
    • 19.2.4 PRODUCT PORTFOLIO
    • 19.2.5 RECENT DEVELOPMENTS
  • 19.3 TEVA PHARMACEUTICAL USA INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
    • 19.3.1 COMPANY SNAPSHOT
    • 19.3.2 REVENUE ANALYSIS
    • 19.3.3 COMPANY SHARE ANALYSIS
    • 19.3.4 PRODUCT PORTFOLIO
    • 19.3.5 RECENT DEVELOPMENTS
  • 19.4 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
    • 19.4.1 COMPANY SNAPSHOT
    • 19.4.2 REVENUE ANALYSIS
    • 19.4.3 COMPANY SHARE ANALYSIS
    • 19.4.4 PRODUCT PORTFOLIO
    • 19.4.5 RECENT DEVELOPMENTS
  • 19.5 NOVARTIS AG
    • 19.5.1 COMPANY SNAPSHOT
    • 19.5.2 REVENUE ANALYSIS
    • 19.5.3 PRODUCT PORTFOLIO
    • 19.5.4 RECENT DEVELOPMENTS
  • 19.6 ABBOTT
    • 19.6.1 COMPANY SNAPSHOT
    • 19.6.2 REVENUE ANALYSIS
    • 19.6.3 PRODUCT PORTFOLIO
    • 19.6.4 RECENT DEVELOPMENT
  • 19.7 ACHE LABORATORIES FARMACEUTICOS S.A.
    • 19.7.1 COMPANY SNAPSHOT
    • 19.7.2 PRODUCT PORTFOLIO
    • 19.7.3 RECENT DEVELOPMENTS
  • 19.8 BAYER AG
    • 19.8.1 COMPANY SNAPSHOT
    • 19.8.2 REVENUE ANALYSIS
    • 19.8.3 PRODUCT PORTFOLIO
    • 19.8.4 RECENT DEVELOPMENTS
  • 19.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 19.9.1 COMPANY SNAPSHOT
    • 19.9.2 REVENUE ANALYSIS
    • 19.9.3 PRODUCT PORTFOLIO
    • 19.9.4 RECENT DEVELOPMENT
  • 19.10 CIPLA INC.
    • 19.10.1 COMPANY SNAPSHOT
    • 19.10.2 REVENUE ANALYSIS
    • 19.10.3 PRODUCT PORTFOLIO
    • 19.10.4 RECENT DEVELOPMENTS
  • 19.11 COVIS PHARMA
    • 19.11.1 COMPANY SNAPSHOT
    • 19.11.2 PRODUCT PORTFOLIO
    • 19.11.3 RECENT DEVELOPMENT
  • 19.12 DR. REDDY'S LABORATORIES LTD.
    • 19.12.1 COMPANY SNAPSHOT
    • 19.12.2 REVENUE ANALYSIS
    • 19.12.3 PRODUCT PORTFOLIO
    • 19.12.4 RECENT DEVELOPMENTS
  • 19.13 ELECTROMED, INC.
    • 19.13.1 COMPANY SNAPSHOT
    • 19.13.2 REVENUE ANALYSIS
    • 19.13.3 PRODUCT PORTFOLIO
    • 19.13.4 RECENT DEVELOPMENTS
  • 19.14 HERSILL
    • 19.14.1 COMPANY SNAPSHOT
    • 19.14.2 PRODUCT PORTFOLIO
    • 19.14.3 RECENT DEVELOPMENTS
  • 19.15 HOME OXYGEN COMPANY
    • 19.15.1 COMPANY SNAPSHOT
    • 19.15.2 PRODUCT PORTFOLIO
    • 19.15.3 RECENT DEVELOPMENT
  • 19.16 HORIZON THERAPEUTICS PLC
    • 19.16.1 COMPANY SNAPSHOT
    • 19.16.2 REVENUE ANALYSIS
    • 19.16.3 PRODUCT PORTFOLIO
    • 19.16.4 RECENT DEVELOPMENT
  • 19.17 INOGEN, INC.
    • 19.17.1 COMPANY SNAPSHOT
    • 19.17.2 REVENUE ANALYSIS
    • 19.17.3 PRODUCT PORTFOLIO
    • 19.17.4 RECENT DEVELOPMENTS
  • 19.18 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
    • 19.18.1 COMPANY SNAPSHOT
    • 19.18.2 REVENUE ANALYSIS
    • 19.18.3 PRODUCT PORTFOLIO
    • 19.18.4 RECENT DEVELOPMENT
  • 19.19 MEDLINE INDUSTRIES, INC.
    • 19.19.1 COMPANY SNAPSHOT
    • 19.19.2 PRODUCT PORTFOLIO
    • 19.19.3 RECENT DEVELOPMENTS
  • 19.20 PFIZER INC.
    • 19.20.1 COMPANY SNAPSHOT
    • 19.20.2 REVENUE ANALYSIS
    • 19.20.3 PRODUCT PORTFOLIO
    • 19.20.4 RECENT DEVELOPMENTS
  • 19.21 SUNOVION PHARMACEUTICALS INC. (A SUBSIDIARY OF SUMITOMO DAINIPPON PHARMA CO., LTD.)
    • 19.21.1 COMPANY SNAPSHOT
    • 19.21.2 REVENUE ANALYSIS
    • 19.21.3 PRODUCT PORTFOLIO
    • 19.21.4 RECENT DEVELOPMENTS
  • 19.22 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • 19.22.1 COMPANY SNAPSHOT
    • 19.22.2 REVENUE ANALYSIS
    • 19.22.3 PRODUCT PORTFOLIO
    • 19.22.4 RECENT DEVELOPMENTS
  • 19.23 TRUEDELL MEDICAL INTERNATIONAL
    • 19.23.1 COMPANY SNAPSHOT
    • 19.23.2 PRODUCT PORTFOLIO
    • 19.23.3 RECENT DEVELOPMENTS
  • 19.24 VIATRIS INC.
    • 19.24.1 COMPANY SNAPSHOT
    • 19.24.2 PRODUCT PORTFOLIO
    • 19.24.3 RECENT DEVELOPMENTS
  • 19.25 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)
    • 19.25.1 COMPANY SNAPSHOT
    • 19.25.2 REVENUE ANALYSIS
    • 19.25.3 PRODUCT PORTFOLIO
    • 19.25.4 RECENT DEVELOPMENTS

20 QUESTIONNAIRE

21 RELATED REPORTS

LIST OF FIGURES

  • FIGURE 1 GLOBAL BRONCHIECTASIS MARKET: SEGMENTATION 71
  • FIGURE 2 GLOBAL BRONCHIECTASIS MARKET : DATA TRIANGULATION 74
  • FIGURE 3 GLOBAL BRONCHIECTASIS MARKET: DROC ANALYSIS 75
  • FIGURE 4 GLOBAL BRONCHIECTASIS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 76
  • FIGURE 5 GLOBAL BRONCHIECTASIS MARKET: COMPANY RESEARCH ANALYSIS 76
  • FIGURE 6 GLOBAL BRONCHIECTASIS MARKET: MULTIVARIATE MODELLING 77
  • FIGURE 7 GLOBAL BRONCHIECTASIS MARKET: INTERVIEW DEMOGRAPHICS 78
  • FIGURE 8 GLOBAL BRONCHIECTASIS MARKET: DBMR MARKET POSITION GRID 79
  • FIGURE 9 GLOBAL BRONCHIECTASIS MARKET: VENDOR SHARE ANALYSIS 80
  • FIGURE 10 GLOBAL BRONCHIECTASIS MARKET: MARKET DRUGS TYPE COVERAGE GRID 81
  • FIGURE 11 GLOBAL BRONCHIECTASIS MARKET: SEGMENTATION 85
  • FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL BRONCHIECTASIS MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028 86
  • FIGURE 13 RISING PATIENT POPULATION SUFFERING FROM BRONCHIECTASIS IS DRIVING THE GLOBAL BRONCHIECTASIS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028 87
  • FIGURE 14 NON-CF BRONCHIECTASIS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL BRONCHIECTASIS MARKET IN 2021 & 2028 87
  • FIGURE 15 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR THE BRONCHIECTASIS MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028 88
  • FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL BRONCHIECTASIS MARKET 98
  • FIGURE 17 NUMBER OF PERSONS AGED 60 YEARS ACROSS SEVERAL REGIONS IN 2017 AND 2050 100
  • FIGURE 18 PREVALENCE OF BRONCHIECTASIS BY AGE IN KOREA POPULATION (2019) 100
  • FIGURE 19 HEALTH SPENDING BY MAJOR SOURCES OF FUNDS 106
  • FIGURE 20 GLOBAL BRONCHIECTASIS MARKET: BY DISEASE TYPE, 2021 114
  • FIGURE 21 GLOBAL BRONCHIECTASIS MARKET: BY DISEASE TYPE, 2019-2028 (USD MILLION) 115
  • FIGURE 22 GLOBAL BRONCHIECTASIS MARKET: BY DISEASE TYPE, CAGR (2021-2028) 115
  • FIGURE 23 GLOBAL BRONCHIECTASIS MARKET: BY DISEASE TYPE, LIFELINE CURVE 116
  • FIGURE 24 GLOBAL BRONCHIECTASIS MARKET: BY SEVERITY, 2021 120
  • FIGURE 25 GLOBAL BRONCHIECTASIS MARKET: BY SEVERITY, 2019-2028 (USD MILLION) 121
  • FIGURE 26 GLOBAL BRONCHIECTASIS MARKET: BY SEVERITY, CAGR(2021-2028) 121
  • FIGURE 27 GLOBAL BRONCHIECTASIS MARKET: BY SEVERITY, LIFELINE CURVE 122
  • FIGURE 28 GLOBAL BRONCHIECTASIS MARKET: BY TYPE, 2021 126
  • FIGURE 29 GLOBAL BRONCHIECTASIS MARKET: BY TYPE, 2019-2028 (USD MILLION) 127
  • FIGURE 30 GLOBAL BRONCHIECTASIS MARKET: BY TYPE, CAGR (2021-2028) 127
  • FIGURE 31 GLOBAL BRONCHIECTASIS MARKET: BY TYPE, LIFELINE CURVE 128
  • FIGURE 32 GLOBAL BRONCHIECTASIS MARKET: BY DRUGS TYPE, 2021 142
  • FIGURE 33 GLOBAL BRONCHIECTASIS MARKET: BY DRUGS TYPE, 2019-2028 (USD MILLION) 143
  • FIGURE 34 GLOBAL BRONCHIECTASIS MARKET: BY DRUGS TYPE, CAGR (2021-2028) 143
  • FIGURE 35 GLOBAL BRONCHIECTASIS MARKET: BY DRUGS TYPE, LIFELINE CURVE 144
  • FIGURE 36 GLOBAL BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, 2021 148
  • FIGURE 37 GLOBAL BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 149
  • FIGURE 38 GLOBAL BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028) 149
  • FIGURE 39 GLOBAL BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 150
  • FIGURE 40 GLOBAL BRONCHIECTASIS MARKET: BY END USER, 2021 156
  • FIGURE 41 GLOBAL BRONCHIECTASIS MARKET: BY END USER, 2019-2028 (USD MILLION) 157
  • FIGURE 42 GLOBAL BRONCHIECTASIS MARKET: BY END USER, CAGR (2021-2028) 157
  • FIGURE 43 GLOBAL BRONCHIECTASIS MARKET: BY END USER, LIFELINE CURVE 158
  • FIGURE 44 GLOBAL BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, 2021 163
  • FIGURE 45 GLOBAL BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 164
  • FIGURE 46 GLOBAL BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028) 164
  • FIGURE 47 GLOBAL BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 165
  • FIGURE 48 GLOBAL BRONCHIECTASIS MARKET: SNAPSHOT (2020) 170
  • FIGURE 49 GLOBAL BRONCHIECTASIS MARKET: BY COUNTRY (2020) 172
  • FIGURE 50 GLOBAL BRONCHIECTASIS MARKET: BY COUNTRY (2021 & 2028) 172
  • FIGURE 51 GLOBAL BRONCHIECTASIS MARKET: BY COUNTRY (2020 & 2028) 173
  • FIGURE 52 GLOBAL BRONCHIECTASIS MARKET: BY DISEASE TYPE (2021-2028) 173
  • FIGURE 53 NORTH AMERICA BRONCHIECTASIS MARKET: SNAPSHOT (2020) 175
  • FIGURE 54 NORTH AMERICA BRONCHIECTASIS MARKET: BY COUNTRY (2020) 177
  • FIGURE 55 NORTH AMERICA BRONCHIECTASIS MARKET: BY COUNTRY (2021 & 2028) 177
  • FIGURE 56 NORTH AMERICA BRONCHIECTASIS MARKET: BY COUNTRY (2020 & 2028) 178
  • FIGURE 57 NORTH AMERICA BRONCHIECTASIS MARKET: BY DISEASE TYPE (2021-2028) 178
  • FIGURE 58 EUROPE BRONCHIECTASIS MARKET: SNAPSHOT (2020) 207
  • FIGURE 59 EUROPE BRONCHIECTASIS MARKET: BY COUNTRY (2020) 209
  • FIGURE 60 EUROPE BRONCHIECTASIS MARKET: BY COUNTRY (2021 & 2028) 209
  • FIGURE 61 EUROPE BRONCHIECTASIS MARKET: BY COUNTRY (2020 & 2028) 210
  • FIGURE 62 EUROPE BRONCHIECTASIS MARKET: BY DISEASE TYPE (2021-2028) 210
  • FIGURE 63 ASIA-PACIFIC BRONCHIECTASIS MARKET: SNAPSHOT (2020) 331
  • FIGURE 64 ASIA-PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2020) 333
  • FIGURE 65 ASIA-PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2021 & 2028) 333
  • FIGURE 66 ASIA-PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2020 & 2028) 334
  • FIGURE 67 ASIA-PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE (2021-2028) 334
  • FIGURE 68 SOUTH AMERICA BRONCHIECTASIS MARKET: SNAPSHOT (2020) 420
  • FIGURE 69 SOUTH AMERICA BRONCHIECTASIS MARKET: BY COUNTRY (2020) 422
  • FIGURE 70 SOUTH AMERICA BRONCHIECTASIS MARKET: BY COUNTRY (2021 & 2028) 422
  • FIGURE 71 SOUTH AMERICA BRONCHIECTASIS MARKET: BY COUNTRY (2020 & 2028) 423
  • FIGURE 72 SOUTH AMERICA BRONCHIECTASIS MARKET: BY DISEASE TYPE (2021-2028) 423
  • FIGURE 73 MIDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: SNAPSHOT (2020) 453
  • FIGURE 74 MIDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY COUNTRY (2020) 455
  • FIGURE 75 MIDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY COUNTRY (2021 & 2028) 455
  • FIGURE 76 MIDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY COUNTRY (2020 & 2028) 456
  • FIGURE 77 MIDDLE EAST AND AFRICA BRONCHIECTASIS MARKET: BY DISEASE TYPE (2021-2028) 456
  • FIGURE 78 GLOBAL BRONCHIECTASIS MARKET: COMPANY SHARE 2020 (%) 507
  • FIGURE 79 NORTH AMERICA BRONCHIECTASIS MARKET: COMPANY SHARE 2020 (%) 508
  • FIGURE 80 EUROPE BRONCHIECTASIS MARKET: COMPANY SHARE 2020 (%) 509
  • FIGURE 81 ASIA-PACIFIC BRONCHIECTASIS MARKET: COMPANY SHARE 2020 (%) 510
Back to Top